BackgroundThe worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in …
Nature Medicine, Published online: 07 June 2026; doi:10.1038/s41591-026-04479-3 As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver dis…
A new report, published in Nature Metabolism, is shedding light on the distinct and underappreciated role of fructose in driving disease, separate from its role as a simple source of calories.
Researchers examine how common dietary sweeteners, including table sugar (sucrose) and high-fructose corn s...
Many people believe that all calories are equal. If two foods contain the same number of calories, they are often seen as having the same effect on the body. However, a new report published in Nature Metabolism suggests this idea may not be completely true. The study highlights that one type of sugar, called fructose, […] The post This type of sugar may cause metabolic disease, study finds appear…
Men’s Health and Metabolic Disease: Why More Men Should Join Clinical Trials Metabolic diseases—such as obesity, type 2 diabetes, and cardiovascular disease—pose a serious threat to men’s health. In fact, men are often at higher risk for developing complications due to biological, hormonal, and behavioral factors that differ from those in women. Despite this, men ... Read more The post Men’s Heal…
